-
E647142-5mgEtilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of
-
E654883-1mlEtilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of
-
E649541-100mgEtiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity Etiocholanolone is a less potent neurosteroid positive allosteric modulator (PAM) of the GABA A receptor than its enantiomer form .In
-
E649541-10mgEtiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity Etiocholanolone is a less potent neurosteroid positive allosteric modulator (PAM) of the GABA A receptor than its enantiomer form .In
-
E649541-25mgEtiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity Etiocholanolone is a less potent neurosteroid positive allosteric modulator (PAM) of the GABA A receptor than its enantiomer form .In
-
E649541-50mgEtiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity Etiocholanolone is a less potent neurosteroid positive allosteric modulator (PAM) of the GABA A receptor than its enantiomer form .In
-
E655901-1mlEtiocholanolone (5β-Androsterone) is the excreted metabolite of testosterone and has anticonvulsant activity Etiocholanolone is a less potent neurosteroid positive allosteric modulator (PAM) of the GABA A receptor than its enantiomer form .In
-
E129476-1gSteroidal aromatase (CYP19) inhibitor.
-
E129476-250mgSteroidal aromatase (CYP19) inhibitor.
-
E129476-5gSteroidal aromatase (CYP19) inhibitor.
-
F610277-100μgfarnesyl diphosphate.
-
F610277-25μgfarnesyl diphosphate.